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Abstract
Cardiovascular diseases are affected by multiple factors 
like genetic as well as environmental hence they reveal 
factorial nature. The evidences that genetic factors 
are susceptible for developing cardiovascular diseases 
come from twin studies and familial aggregation. Differ-
ent ethnic populations reveal differences in the preva-
lence coronary artery disease (CAD) pointing towards 
the genetic susceptibility. With progression in molecular 
techniques different developments have been made to 
comprehend the disease physiology. Molecular markers 
have also assisted to recognize genes that may provide 
evidences to evaluate the role of genetic factors in cau-
sation of susceptibility towards CAD. Numerous studies 
suggest the contribution of specific “candidate genes”, 
which correlate with various roles/pathways that are 
involved in the coronary heart disease. Different studies 
have revealed that there are large numbers of genes 
which are involved towards the predisposition of CAD. 
However, these reports are not consistent. One of the 
reasons could be weak contribution of genetic suscep-
tibility of these genes. Genome wide associations show 
different chromosomal locations which dock, earlier 
unknown, genes which may  attribute to CAD. In the 
present review different ApoAI-CIII-AIV  gene clusters 
have been discussed.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Cardiovascular disease analysis requires holis-
tic approach using genomic, epigenomic and exposomic 
techniques to improve the quality of life of patients and 
contribution towards personalised medicine.
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INTRODUCTION
Coronary artery disease (CAD), is mostly fatal if  remain 
untreated result into atherosclerosis in the epicardial 
coronary arteries[1]. Atherosclerotic plaques progressively 
narrow the coronary artery lumen and impair antegrade 
myocardial blood flow. This reduction in coronary artery 
flow may lead to a myocardial infarction.
Cardiovascular disease is a multifarious disorder 
showing large diversity of  phenotypes. The accurate, and 
analogous phenotypic evidences are crucial for detailed 
understanding of  the affiliation between disease and 
genes, as well as understanding the role of  various extrin-
sic factors on different component of  various genotypes. 
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This complexity also contributes to difficulties in diagno-
sis and prognosis of  the disease. Diagnostic difficulties 
also hamper the optimal and personalised treatment for 
patients. In recent years the role of  genetic variability 
on the development of  CAD has been extensively been 
studied[1,2] which is impacting upon our understanding 
of  phenotypic outcomes and clinical complications. New 
developments in genomics, epigenomics and exposomics 
(environmental risk factors across the life span) would 
result into the improved understanding of  the different 
phenotypes observed in CAD and would help in the bet-
ter regimen of  treatment. In the last century, there has 
been rapid increases in the global prevalence of  CAD, 
which has become the important cause of  cardiovascular 
mortality all over the world, is > 4.5 million deaths in the 
developing countries. By 2020, it is predictable that CAD 
will be the major source of  disease burden universally[2]. 
The prevalence of  CAD varies in different ethnic groups 
which may show higher/lower genetic and environmen-
tal susceptibilities. India has also witnessed consistent 
increases in the prevalence of  CAD over the past few de-
cades and could become the number one killer if  appro-
priate interventions are not planned and implemented. In 
Table 1 the incidence of  CAD is shown in different parts 
of  India.
It has been reported that CAD is increasing in a linear 
fashion as it has increased from 4% in 1960 to 11% in 
2001 i.e., almost every 25th individual in 1960 was having 
CAD, while in 2001 every 9th individual was having CAD. 
The CAD is declining internationally among Indians 
settled abroad, whereas, these rates are growing in the In-
dian subcontinent. Presently, 10%-12% of  metropolitan 
Indians have CAD compared to 3% of  the United States 
population. Many studies document that Asian Indians 
are at 3-4 times greater risk of  CAD than white Ameri-
cans/Europeans, 6 times higher than Chinese, and almost 
20 times higher than Japanese[3-7]. CAD prevalence has 
increased from 3.5% in the 1960s to 9.5% in the 1990s in 
urban populations of  India[8]. Current studies recognized 
occurrence of  CAD to be 13.9% in the urban south In-
dians, 9.6% in urban north Indians[9-11]. In 1990s, 33% of  
cardiovascular deaths have been reported from India[12] 
and it is likely that deaths from non-communicable dis-
eases such as CAD will increase two times higher i.e., 4.5 
million in 1998 to 8 million in 2020 in India[13].
As CAD has a multifactorial nature and the occur-
rence of  the familial clustering in CAD led investigators 
to start searching for susceptibility genes. In Figure 1 dif-
ferent risk factors involved in the causation of  CAD are 
summarized. 
It is vital to keep in mind that certain genes may show 
population specific effects. There are hundreds of  genes 
known to have functional allelic variations that may be 
important for determining an individual’s vulnerability to 
CAD. There is much argument on results of  published 
epidemiological studies until now. The differences may be 
due to differences in the techniques used or the popula-
tion used to calculate the incidence, prevalence and other 
risks. It has been proposed that if  multiple markers are 
used for assigning the risk, the results would be more 
conclusive clinically. Most important reason of  concern 
in developing countries like India is the incomplete de-
tection, treatment and control of  CAD risk factors. The 
benefits of  addressing the root cause of  CAD, such as 
inflammation, smoking and cholesterol, together with 
preventive methodology will be useful in improving qual-
ity of  life and saving lives. This in turn may be translated 
into preventive approaches to help reduce the risk of  
CAD using genetic and epigenetic approaches. Although 
CAD mortality in the Indians is highest than other 
populations[14,15], the reason for increased risk, which has 
been recorded in both the Asian immigrants and among 
Indians in urban India; are not yet clear hence more sys-
tematic and comprehensive studies are required to under-
stand the spectrum of  genetic and epigenetic influences 
on CAD.
GENETIC BASIS OF CAD
Atherosclerosis involves multiple factors, hence un-
derstanding the genetic and environmental basis of  
this complex disease requires holistic approaches[16-18]. 
A range of  candidate genes (e.g., APOE, APOB, LPL, 
iNOS, ACE, COX2, CD14, P-Selectin, E-Selectin, MTHFR, 
PON1, TNFα ) have been investigated in relation to initi-
ation, development and progression of  CAD[16-18]. A large 
number of  studies using of  candidate genes and genome-
wide association analyses have shown some promising 
signals, but only a few have been confirmed to some ex-
tent which may be playing a role in CAD. 
There are very few examples where single genes 
have played a role in causing atherosclerosis[19,20]. Mostly, 
CAD is caused by the environmental factors however the 
risk increases when some risk associated genes are also 
present. Research on identical twins consistently shows 
significant genetic effect in the development of  CAD or 
its risk factors (Table 2). Heritability for CHD vary from 
40% to 60%[21,22], suggesting a strong role of  genes in the 
development of  the disease. A detailed analysis of  the 
many known CAD susceptibility genes and studies is be-
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  City Prevalence Ref.
  Urban population
     Chandigarh (6.60%) Sarvotham et al[49]
     Rohtak (3.80%) Gupta et al[50]
     Jaipur     (7.60%) Gupta et al[51]
     Delhi (9.70%) Chada et al[52]
  Rural population
     Jaipur      (3.50%) Gupta et al[53]
     Ludhiana (3.08%) Wander et al[54]
  South Indians
     Tamil Nadu (14.30%) Ramachandran et al[55]
     Tamil Nadu (11.00%) Mohan et al[56]
  Migrant Indians
     London, United Kingdom (17.00%) Bahl et al[57]
     Illinois, United States (10.00%) Enas et al[3]
Table 1  Prevalence of coronary artery disease in different 
Indian surveys
yond the scope of  this overview. This overview will focus 
on selected candidate genes in the ApoAI-CIII-AIV gene 
region.
SINGLE GENE DISORDERS AND CAD
Familial hypercholesterolemia 
Familial hyper cholesterolemia (FH) is a classic genetic 
disease in which increased cholesterol, tendon xantho-
mas, and early heart disease segregates together. Joseph 
Goldstein and Michael Brown showed that FH results 
from mutations in the low-density lipoprotein (LDL) 
receptor, which leads to impaired binding, internalization 
and degradation of  LDL. Dose dependent relationship 
was observed, homozygotes patients had higher levels of  
cholesterol (> 600 mg/dL), whereas heterozygotes had 
levels of  approximately 400 mg/dL. This variable pene-
trance is modified by genes and other risk factors such as 
diet, smoking, and physical activity level[23]. Heterozygote 
frequency for this disease relatively high, approximately 
1 in 500[24] in most populations, however DNA screening 
and effective treatments are available now[25,26].
Familial defective apolipoprotein B causing 
hypercholesterolemia
This comparatively common hypercholesterolemia (ap-
proximately 1 in 800), results from mutations in the ma-
jor protein of  LDL called Apolipoprotein B (ApoB). The 
mutations in ApoB prevent LDL binding to the LDL 
receptor. The majority of  patients of  this disorder carry a 
dominant mutation (codon 3500) and have lower choles-
terol levels compared to FH patients. Other single-gene 
CHD/CAD traits are rare and of  lower clinical/popula-
tion significance[20].
CANDIDATE GENES AND CAD
During last 30 years, there have been many advancements 
in molecular genetic technology, development of  sophis-
ticated statistical tools and analyses which have contrib-
uted to improvements in human genetic research. One of  
the early developments was positional cloning technique, 
which allowed genetic mapping of  many Mendelian dis-
eases and traits. However for complex diseases, which 
involve many genes and environmental influences, this 
technique did not provide any major insights into genetic 
basis.  Majority of  our understanding of  the genetic basis 
of  CAD/CHD has been gained from studies of  “candi-
date genes,” and more recently genome wide association 
(GWA) studies. These population based studies have pro-
vided further insights into genetic susceptibilities/contri-
butions to complex diseases. Some examples of  these are 
given below.
APOLIPOPROTEIN E AND APOAI-CIII-AIV-
AV GENE CLUSTER
Apolipoprotein E (ApoE) is one of  the extensively stud-
ied genetic locus as it plays a pivotal role in lipid metabo-
lism and mediates the uptake of  chylomicron and very 
low-density lipoprotein (VLDL) remnants. Utermann 
and colleagues[27] identified genetic polymorphism at 
ApoE locus and its association with cholesterol levels 
and type Ⅲ hyperlipidemia. The polymorphism and its 
CAD associations have been replicated in many global 
populations. E3 allele is the most common (approximately 
60%) followed by E4 allele (approximately 30%) and E2 
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  Risk factors with a significant genetic component (heritability)
     Elevated LDL and VLDL cholesterol (40%-60%)
     Low HDL cholesterol (45%-75%)
     Elevated triglycerides (40%-80%)
     Increased body mass index (25%-60%)
     Elevated systolic blood pressure (50%-70%)
     Elevated diastolic blood pressure (50%-65%)
     Elevated lipoprotein(a) levels (90%)
     Elevated homocysteine levels (45%)
     Type 2 diabetes mellitus (40%-80%)
     Elevated fibrinogen (20%-50%)
     Elevated C-reactive protein (40%)
     Elevated homocysteine levels (45%)
     Gender
     Age
     Family history
  Environmental risk factors
     Smoking
     Diet
     Exercise
     Infection
  Foetal environment
     Air pollution (particulates)
Table 2  Genetic and environmental risk factors for coronary 
heart disease
Risk factors for coronary heart disease  can be subdivided into those that 
are determined significantly by genetic differences and those that are 
largely environmental (Based on Lusis et al[58] 2004). VLDL: Very low den-
sity lipoprotein; LDL: Low density lipoprotein; HDL: High density lipo-
protein.
Cardiovascular
risk
Age, Place,
Sex
Family history
Smoking
Inflammation
Obesity
Hypertension
 Diabetes
Abnormal
Lipid
metabolism
Genetic 
susceptibility
Figure 1  Cardiovascular risk factors.
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reported negative or inconsistent results[42-46]. In addition 
there are many other SNPs involved in the inflammation 
and cell signalling with CAD and/or MI, some of  these 
are summarized in Table 3.
One of  the limitations of  case control studies is that 
many false positive or false negative associations may 
emerge between different genetic markers and complex 
diseases like CAD. The reason for such results are: (1) 
controls are not properly selected; (2) sample size of  
both controls and cases because of  which accurate power 
of  the study is not generated and replication of  results 
is not possible; and (3) position of  single-nucleotide 
polymorphisms (SNP’s) in terms of  their effect on 
transcription of  gene or protein expression. In general, 
results of  small sample size studies (200-300 patients 
and control subjects) should be interpreted with caution 
and should be replicated with larger sample sizes. It is 
important to confirm that genotype distributions are not 
skewed, especially in the control group. Large deviations 
from the Hardy-Weinberg equilibrium, may suggest that 
the control group is not necessarily the representative 
of  healthy and randomly sampled individuals. This de-
parture may also highlight issues with genotype scoring. 
Recent genome-wide sequencing research has revealed 
extensive level of  variation and heterogeneity between 
individuals and populations, which should be considered 
when choosing SNPs and interpreting SNP data. Some 
of  the early SNP association studies failed to include the 
effect of  the polymorphism on gene expression or pro-
tein function and genotype-phenotype correlations. This 
information could reveal if  an SNP is the actual cause or 
solely a marker which may be in linkage disequilibrium 
another causal variant. These analyses could provide 
significant clues for understanding the pathophysiologic 
mechanisms behind clinical outcomes. It is important to 
correct/control for the age, gender, ethnicity, and other 
confounders in heart disease genetic association studies. 
There should be a holistic approach to understand the 
role of  genes, environment and life style factors in CAD 
susceptibilities and progression.
Recently, genetic analyses have expanded to whole 
genome sequence analysis and genome-wide associa-
tion studies (GWAS) as these analyses eliminates biases 
in the selection of  the candidate genes. A number of  
GWAS studies have identified new loci in previously un-
suspected genomic regions. These analyses have shown, 
novel biological pathways involved in the disease states 
and development of  novel therapies. Many recent studies 
have shown only limited evidences may exist where the 
genetic variants may be associated with MI or only with 
CAD. A care has to be taken in interpreting the GWAS 
data as large number of  variant alleles may be found but 
one should consider only elegant systems genetics ap-
proach to Plaisier et al[47] used similar approach and found 
that FADS3 is a causal gene for familial combined hyper-
lipidemia (FCHL) and elevated triglycerides in Mexicans. 
The authors used network gene co-expression analysis 
and SNP data to assign a function to the genetic variants 
(approximately 10) in world populations. E4 allele carri-
ers have increased plasma cholesterol levels compared to 
E3 allele carriers while E2 carriers have decreased plasma 
cholesterols. The allelic variation at ApoE locus explains 
approximately 5% of  the variation in cholesterol levels[28]. 
Type Ⅲ hyperlipidemia, a relatively rare phenotype, are 
homozygous for the E2 allele, but not all E2 homozy-
gous individuals have this disorder[29]. Therefore, geno-
type-phenotype relationships may require contribution of  
other genetic or environmental factors. 
In addition to ApoE, there is now strong evidence 
that mutations in hepatic lipase influence the levels of  
high-density lipoprotein (HDL)[30], and the ApoAI-CIII-
AIV-AV locus contributes to plasma triglyceride levels[31]. 
Many studies have shown that Lp(a) levels are strongly 
influenced by Apo(a) gene[32] In addition, both hepatic li-
pase and the ApoAI-CIII-AIV-AV cluster influence LDL 
particle size, which significantly contributes to CHD 
risk[33]. However, taken together, these genetic differences 
only explain a small amount of  variation in plasma lipids 
and CHD/CAD phenotypes. 
Dyslipidemia, a metabolic disorder, caused due to the 
defects in the synthesis, processing and catabolism of  
lipoprotein particles. Increased total cholesterol (TC)[34], 
triglyceride (TG)[35], LDL cholesterol (LDL-C)[36], and 
apolipoprotein (Apo)B[37], together with lower levels of  
ApoA1[37] and HDL cholesterol (HDL-C)[38] have been 
found to increase coronary artery disease (CAD) risk. 
Epidemiological and clinical studies have documented 
that above genetic factors/polymorphisms play a sig-
nificant role in dyslipidemia[39] susceptibilities along with 
environmental factors.  Twin and family studies suggest 
there are considerable genetic contributions in the inter-
individual variation in plasma lipid phenotypes with the 
heritability estimates ranging from 40%-60%[40]. It has 
been suggested that understanding variation at these loci 
along with other newer genetic loci will provide a better 
understanding of  the disease processes and contribution 
to personalized medicine. 
ApoA1, is the main protein component of  HDL-C, 
it functions in the activation of  lecithin: cholesterol acyl-
transferase, and facilitates the reverse cholesterol trans-
port from peripheral tissues[41]. ApoC3, is a 79-amino-
acid protein formed mainly in the liver, is one of  the 
major component of  chylomicrons and VLDL and a 
minor component of  HDL. ApoC3 prevents lipoprotein 
lipase and plays  a key role in the catabolism of  TG-rich 
lipoproteins. ApoA5 is detectable in very low-density 
lipoprotein, HDL, and chylomicrons and its concentra-
tions are low compared to other apolipoproteins. Human 
ApoA1/C3/A5 genes resides in the ApoA1/C3/A4/
A5 gene cluster on chromosome 11q23-q24[42-45]. The 
ApoA1/C3/A4/A5 gene cluster has emerged as a sig-
nificant risk factor for hypertriglyceridemia and athero-
sclerosis[41,42]. A number of  studies have shown significant 
associations between single nucleotide polymorphisms 
(SNPs) in the ApoA1/C3/A4/A5 gene cluster and raised 
plasma or serum lipid levels in humans, while others have 
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rs3737787 (1q21-q23) in USF1 gene, which was previ-
ously identified to be associated with FCHL. It is envis-
aged that new methods like Network medicine[48] will play 
an important role in these analyses and the advancement 
of  our understanding of  pathophysiological mechanisms 
of  diseases like CAD and MI.
CONCLUSION
This overview has highlighted some of  the important 
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  Gene Polymorphism Ref. Suggested results
  CRP 1059G/C Zee et al[59] No significant association with non-fatal MI, stroke or 
cardiovascular death
  ICAM-1 Lys-469-glu Jiang et al[60] Association with MI and CAD
  E-selectin Ser-128-Arg, Leu-554-phe, G98T Wenzel et al[61] Associated with angiographic proof of severe CAD in patients < 
50 yr
Ser-128-Arg, G98T Herrmann et al[62] No association with MI
Zheng et al[63]  T allele more common in younger patients with angiographic 
CAD
Ser-128-Arg Ye et al[64] Association with early-onset CAD
  P-selectin Pro715 Herrmann et al[65], Kee et al[66] Possibly has a protective role from MI
S290N, N562D, V599L, T715P, T741T Tregouet et al[67] Protective effect of the P715; S290N and N562D associated with 
MI, when carried by certain haplotype
C-2123G, A-1969G, Thr715Pro Barbaux et al[68] Polymorphisms associated with P-selectin levels but not with MI
  TNF-α  and β -863C/A, -308G/A (TNF-α), 252G/A 
(TNF-β)
Koch et al[69] No association of TNF or IL-10 polymorphisms with MI or CAD
  TNF-α Five polymorphisms Herrmann et al[65] No association to MI or CAD
  TNF-α  and β TNF- α 308 G/A , Padovani et al[70] No association to MI
TNF- β 252 A/G
  TNF-α  and β TNF- β 308 G/A , TNF- β 252 A/G Keso et al[71] No association to old MI by autopsy or CAD
  TNF-α 308 G/A Francis et al[72] No association to angiographic CAD
  IL-1 cluster IL-1α (-889), IL-1b (-511), Francis et al[72] No association to angiographic CAD
IL-1β (+3953), IL-1RA intron 2 VNTR IL-1RA VNTR allele 2 associated with single-vessel CAD
  IL-1-RA IL-1RA intron 2 VNTR Manzoli et al[73] No clear-cut association to CAD or MI
  IL-1 cluster IL-1β 511 C/T, IL-1RA intron 2 VNTR Vohnout et al[74] No association to angiographic CAD with either polymorphisms
  IL-1-RA IL 1RN-VNTR Zee et al[75] No association with risk for future MI
  IL-1 β , IL-RA IL-1β 511 C/T, IL-1RA intron 2 VNTR Momiyama et al[76] IL-1 β (-511)C/C and IL-1Ra (intron 2)2-or 3- repeat allele both 
associated with CAD, association with MI only in patient who are 
seropositive for Chlamydia pneumoniae
  IL-6 IL-6 G (-174)C promoter polymorphism Nauck et al[77] No association with the risk for CAD or MI
-174 (G/C), -572 (G/C), -596 (G/A), 
+528 I/D
Georges et al[78] -174 C associated with MI (OR = 1.34)-174 C more frequent in 
patients with two or fewer stenosed vessels than in patients with 
three vessel lesions
  IL-10 3 IL-10 promotor polymorphisms 
(1082G/A, - 819C/T and -592C/A)
Koch et al[69] No association with MI or CAD
7 polymorphisms Donger et al[79] No association with risk for MI
  TGF- β 1 29 T/C Yokota et al[80] T allele is a risk factor for MI in middle-aged Japanese men
-509T Wang et al[81] No association with CAD
7 polymorphisms Cambien et al[82] No association with degree of angiographic CAD, Pro25 allele 
associated with MI in some regions.
  Stromelysin
  (MMP-3)
5 polymorphisms Syrris et al[83] No association of either polymorphisms with CAD
5A-117/6A promoter polymorphism 
(5A/6A)
Schwarz et al[84] No association with the risk for MI, 6A allele marker for 
progression of CAD
5A/6A Terashima et al[85] 5A allele associated with risk for MI
5A/6A Kim et al[86] 5A allele associated with stable angina
5A/6A Humphries et al[87] 6A genotypes at greater risk for CAD related events in 
nonsmokers, 5A/5A genotypes amplifies risk in smokers
5A/6A Ye et al[88] Homozygosis for 6A associated with greater progression of 
angiographic CAD
  PECAM-1
  (CD31)
Val 125Leu, Asn563Ser and Gly670Arg Sasaoka et al[89] 563Ser/Ser and 670Arg/Arg genotypes associated with MI
Val 125Leu, Asn563Ser Wenzel et al[90] 125 Val and 563Asn associated with early onset of CAD (< 50 yr)
Leu 125Val, Ser563Asn Song et al[91] 125Val and 563Asn associated with CAD
Val125Leu Gardemann et al[92] No association with MI; weak association of Val125 with CAD in 
low-risk patients without HTN or DM (OR = 1.54; 95%CI: 1.03-2.3)
Table 3  Example of association studies of factors involved in inflammation and cell signalling with coronary artery disease and/or 
myocardial infarction
CRP: C-reactive protein; DM: Diabetes mellitus; HTN: Hypertension; ICAM: Intercellular adhesion molecule; IL: Interleukin; MI: Myocardial infarction; 
MMP: Matrix metalloproteinase; PECAM: Platelet endothelial cell adhesion molecule; TGF: Transforming growth factor; TNF: Tumor necrosis factor; 
VNTR: Variable number of tandem repeats.
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challenges regarding the use of  genetic approaches to 
investigate complex diseases. The recent research us-
ing genomic, epigenomics and exposomic approaches 
is providing a range of  patient centric tools which will 
help better classification of  phenotypes and personalised 
medicine for CAD patients. The mechanisms underlying 
the association of  these loci to CAD/MI remain largely 
unknown and the effects are relatively small. Hence the 
future challenges are (1) discovering new genetic variants 
through large-scale meta-analyses, using pathway-based 
approaches, and high throughput sequencing; (2) illustrat-
ing the mechanisms for the identified loci to CAD; and (3) 
translating the findings from CAD- GWASs and epigene-
tic analyses to novel and optimized therapeutic strategies.
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